Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Aeon Biopharma Sub Inc. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active matters are distributed across 3 distinct examiners and 2 distinct art units. This distribution indicates that the company's patenting activities are spread across multiple technical sub-specialties or administrative groups within the patent office, though there is some concentration within the art units.
LALONDE, ALEXANDRA ELIZABETH is identified as the busiest examiner for the portfolio, with 1 pending office action currently assigned. This 1 busiest examiner pending case is part of the company's total active workload of 3 pending office actions. The involvement of 2 distinct art units and 3 distinct examiners suggests a diversified prosecution landscape where active files are being reviewed by different individuals. This structure requires the company to manage multiple simultaneous interactions across the Biotechnology & Pharmaceuticals sector. The data highlights a portfolio that is technically or administratively varied across its 3 pending office actions. With 3 distinct examiners involved, the company faces a range of examiner perspectives, which may influence the overall consistency of the prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LALONDE, ALEXANDRA ELIZABETH | 1 | 71.1% | +33.0% |
| IANNUZO, NATALIE NMN | 1 | 12.5% | +71.4% |
| JACKSON-TONGUE, LAKIA J | 1 | 69.0% | +20.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278937 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE | IANNUZO, NATALIE NMN | 31d overdue |
| 17911089 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS | JACKSON-TONGUE, LAKIA J | 34d |
| 18682352 | SINGLE-USE NEUROTOXIN FORMULATIONS AND PACKAGING | LALONDE, ALEXANDRA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278937 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE | IANNUZO, NATALIE NMN | 31d overdue |
| 17911089 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS | JACKSON-TONGUE, LAKIA J | 34d |
| 18682352 | SINGLE-USE NEUROTOXIN FORMULATIONS AND PACKAGING | LALONDE, ALEXANDRA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682352 | SINGLE-USE NEUROTOXIN FORMULATIONS AND PACKAGING | LALONDE, ALEXANDRA ELIZABETH | — | §102§103§112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18278937 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING HEADACHE | IANNUZO, NATALIE NMN | 1653 | §103§112DP | Final Rejection | 31d overdue | Pending | Aug 25, 2023 |
| 17911089 | NEUROTOXIN COMPOSITIONS FOR USE IN TREATING CARDIOVASCULAR DISORDERS | JACKSON-TONGUE, LAKIA J | 1645 | §102§103 | Final Rejection | 34d | Pending | Sep 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial